Literature DB >> 20587123

Are we hitting immunity targets? The 2006 age-specific seroprevalence of measles, mumps, rubella, diphtheria and tetanus in Belgium.

H Theeten1, V Hutse, N Hens, Y Yavuz, K Hoppenbrouwers, P Beutels, R Vranckx, P Van Damme.   

Abstract

Susceptibility to vaccine-preventable diseases in Belgium in 2006 was estimated from a serum survey. Immunoglobulins against measles, mumps, rubella (MMR) and diphtheria at all available ages (1-65 years), and against tetanus in >40-year-olds, were measured by ELISA. Age-standardized overall seronegativity for MMR was low (3·9%, 8·0%, 10·4%, respectively). However, the World Health Organization's targets for measles elimination were not met in 5- to 24-year-olds and about 1 in 7 women at childbearing age (15-39 years) were seronegative for rubella. In adults >40 years, tetanus immunity (87·2%, >0·16 IU/ml) largely exceeded diphtheria immunity (20-45%, >0·1 IU/ml). Despite free universal vaccination against MMR for more than 20 years and against diphtheria and tetanus for almost 60 years, our study revealed specific age groups remaining at risk for infection with these pathogens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20587123     DOI: 10.1017/S0950268810001536

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  19 in total

1.  Cytomegalovirus seropositivity is associated with herpes zoster.

Authors:  Benson Ogunjimi; Niel Hens; Richard Pebody; Hilde Jansens; Holly Seale; Mark Quinlivan; Heidi Theeten; Herman Goossens; Judy Breuer; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Seroepidemiology of pertussis in Hangzhou, China, during 2009-2017.

Authors:  Yuyang Xu; Erping Xu; Shijun Liu; Wei Zheng; Xuechao Zhang; Jian Du; Xiaoping Zhang; Jun Wang; Xinren Che; Wenwen Gu; Yan Liu
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

3.  Development of human monoclonal antibodies to diphtheria toxin: A solution for the increasing lack of equine DAT for therapeutic use?

Authors:  Kris Huygen
Journal:  Virulence       Date:  2016-05-19       Impact factor: 5.882

4.  Maternal mumps antibodies in a cohort of children up to the age of 1 year.

Authors:  E Leuridan; N Goeyvaerts; N Hens; V Hutse; P Van Damme
Journal:  Eur J Pediatr       Date:  2012-03-07       Impact factor: 3.183

5.  Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, and B. Pertussis in young adults of Madrid, Spain.

Authors:  Alba González-Escalada; Laura García-García; Pablo Viguera-Ester; Patricia Marín-García; Jesus García; Angel Gil-de-Miguel; Ruth Gil-Prieto
Journal:  Hum Vaccin Immunother       Date:  2013-06-21       Impact factor: 3.452

6.  Seroepidemiology of tetanus in Hangzhou from 2009 to 2018.

Authors:  Yuyang Xu; Yan Liu; Jian Du; Wei Zheng; Shijun Liu; Xuechao Zhang; Xiaoping Zhang; Jun Wang; Xinren Che; Wenwen Gu; Wei Jiang
Journal:  Hum Vaccin Immunother       Date:  2020-05-27       Impact factor: 3.452

7.  Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China.

Authors:  Dandan Liu; Xiaoping Cheng; Shi Wei; Lin Yuan; Changhui Chen; Kaihu Yao
Journal:  Hum Vaccin Immunother       Date:  2021-01-30       Impact factor: 3.452

8.  High risk of a large measles outbreak despite 30 years of measles vaccination in The Netherlands.

Authors:  L Mollema; G P Smits; G A Berbers; F R Van Der Klis; R S Van Binnendijk; H E De Melker; S J M Hahné
Journal:  Epidemiol Infect       Date:  2013-08-06       Impact factor: 4.434

9.  Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

Authors:  Christina Poethko-Müller; Annette Mankertz
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

10.  Universal hepatitis B vaccination in Belgium: impact on serological markers 3 and 7 years after implementation.

Authors:  H Theeten; V Hutse; K Hoppenbrouwers; P Beutels; P VAN Damme
Journal:  Epidemiol Infect       Date:  2013-05-21       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.